# US 2024/0199746 A1 · Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199746 A1
- Document ID: US20240199746A1
- Status: Published application
- Kind: A1
- Application number: 18/402,642
- Filed: 2024-01-02
- Published: 2024-06-20
- Earliest claimed: 2016-04-15
- Assignees: BioAtla, Inc.
- Applicants: BioAtla, Inc.
- Inventors: Jay M. Short; Hwai Wen Chang; Gerhard Frey
- Web page: https://patentgrep.com/patent/US20240199746A1

## CPC

- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61P 35/00: Antineoplastic agents
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An antibody or antibody fragment having a heavy chain variable region and/or light chain variable region that specifically binds to Ax1 protein. Immunoconjugates, pharmaceutical compositions and kits comprising the antibodies and antibody fragments are also provided. Also disclosed are methods of treating Ax1-expressing cancers using the antibodies, antibody fragments, immunoconjugates and pharmaceutical compositions of the present invention.

## Claims

### Claim at position 1

-20. (canceled)

### Claim 21

A method of treating an AXL protein expressing cancer comprising administering to a patient a therapeutically effective amount of an immunoconjugate comprising
an antibody or antibody fragment that specifically binds to Ax1 protein, said antibody or antibody fragment comprising a heavy chain variable region including three complementarity determining regions having H1, H2, and H3 sequences, and a light chain variable region including three complementarity determining regions having L1, L2, and L3 sequences, wherein:
(a) the H1 sequence is X1GX2X3MX4 (SEQ ID NO: 1);
(b) the H2 sequence is LIKX5SNGGTX6YNQKFKG (SEQ ID NO: 2); and
(c) the H3 sequence is GX7X8X9X10X11X12X13X14DYX15X16 (SEQ ID NO: 3),
wherein
X1 is T or A or W,
X2 is H or A,
X3 is T or I,
X4 is N or I,
X5 is P or N,
X6 is S or I or T,
X7 is H or D or E or P or R or W,
X8 is Y or N,
X9 is E or A or D or F or G or H or I or L or M or N or R or V or Y,
X10 is S or D or M or N or Q,
X11 is Y or C or E or P,
X12 is F or E or N or S or T or V,
X13 is A or D or G or L or Y,
X14 is M or E or F,
X15 is W or A or D or H or L or N or P or R or T,
X16 is G or H, and
(d) the L1 sequence is KASQDX17X18SX19VX20 (SEQ ID NO: 4);
(e) the L2 sequence is X21X22X23TRX24T (SEQ ID NO: 5); and
(f) the L3 sequence is QEX25X26SX27X28X29X30 (SEQ ID NO: 6),
wherein
X17 is V or D or G or N or W,
X18 is S or V,
X19 is A or L or M,
X20 is A or D or N or Q,
X21 is W or F,
X22 is A or I or N or P or Q,
X23 is S or D,
X24 is H or D,
X25 is H or C or F or I or L or Q or S or T or V or Y,
X26 is F or C or D or E or G or N or S,
X27 is T or C or P,
X28 is P or A or C or D or E or H or K or S or T or V or W,
X29 is L or G or R, and
X30 is T or I or R; and
at least one agent selected from the group consisting of a chemotherapeutic agent, a radioactive atom, a cytostatic agent and a cytotoxic agent; and
wherein the AXL protein expressing cancer is selected from the group consisting of small cell lung cancer, non-small cell lung cancer, renal cancer, liver cancer, melanoma, bladder cancer, cervical cancer, hepatic carcinoma, gastric cancer, sarcoma and kidney cancer.

### Claim 22 (depends on 21)

The method of claim 21, wherein the heavy chain variable region of the antibody or antibody fragment is encoded by a DNA sequence selected from the group consisting of sequences of SEQ ID NOS: 11-13.

### Claim 23 (depends on 21)

The method of claim 21, wherein the light chain variable region of the antibody or antibody fragment is encoded by a DNA sequence selected from the group consisting of sequences of SEQ ID NOS: 7-10.

### Claim 24 (depends on 21)

The method of claim 21, wherein the heavy chain variable region of the antibody or antibody fragment is encoded by the DNA sequence of SEQ ID NO: 12 and the light chain variable region of the antibody or antibody fragment is encoded by the DNA sequence of SEQ ID NO: 9.

### Claim 25 (depends on 21)

The method of claim 21, wherein the antibody or antibody fragment has a higher binding affinity to the Ax1 protein at a value of a condition in a tumor microenvironment in comparison with a different value of the same condition that occurs in a non-tumor microenvironment.

### Claim 26 (depends on 25)

The method of claim 25, wherein the condition is pH.

### Claim 27 (depends on 26)

The method of claim 26, wherein the pH in the tumor microenvironment is in a range of from 5.8 to 7.0 and the pH in the non-tumor microenvironment is in a range of 7.2-7.6.

### Claim 28 (depends on 21)

The method of claim 21, wherein the antibody or antibody fragment has a ratio of binding affinity to the Ax1 protein at a value of a condition in a tumor microenvironment to a binding affinity to the Ax1 protein at a different value of the same condition in a non-tumor microenvironment of at least about 1.5:1.

### Claim 29 (depends on 21)

The method of claim 21, wherein the antibody or antibody fragment is selected from the group consisting of a chimeric antibody, a multispecific antibody and a humanized antibody.

### Claim 30 (depends on 21)

The method of claim 21, wherein the immunoconjugate comprises at least two agents.

### Claim 31 (depends on 21)

The method of claim 21, wherein the antibody or antibody fragment and the at least one agent are covalently bonded to a linker molecule.

### Claim 32 (depends on 21)

The method of claim 21, wherein the at least one agent is selected from the group consisting of maytansinoids, auristatins, dolastatins, calicheamicin, pyrrolobenzodiazepines, and anthracyclines.

### Claim 33 (depends on 21)

The method of claim 21, wherein the cancer is non-small cell lung cancer.

### Claim 34 (depends on 21)

The method of claim 21, wherein the cancer is sarcoma.

### Claim 35 (depends on 34)

The method of claim 34, wherein the sarcoma is osteosarcoma.

### Claim 36 (depends on 22)

The method of claim 22, wherein the light chain variable region of the antibody or antibody fragment is encoded by a DNA sequence selected from the group consisting of sequences of SEQ ID NOS: 7-10.

### Claim 37 (depends on 27)

The method of claim 27, wherein the pH in the tumor microenvironment is about 6.0 and the pH in the non-tumor microenvironment is about 7.4.

### Claim 38 (depends on 22)

The method of claim 22, wherein the antibody or antibody fragment has a ratio of binding affinity to the Ax1 protein at a pH of 5.8 to 7.0 of a tumor microenvironment to a binding affinity to the Ax1 protein at a pH of 7.2 to 7.6 in a non-tumor microenvironment of at least about 1.5:1.

### Claim 39 (depends on 36)

The method of claim 36, wherein the antibody or antibody fragment has a ratio of binding affinity to the Ax1 protein at a pH of 5.8 to 7.0 of a tumor microenvironment to a binding affinity to the Ax1 protein at a pH of 7.2 to 7.6 in a non-tumor microenvironment of at least about 1.5:1.

### Claim 40 (depends on 36)

The method of claim 36, wherein the antibody or antibody fragment has a ratio of binding affinity to the Ax1 protein at a pH of 5.8 to 7.0 of a tumor microenvironment to a binding affinity to the Ax1 protein at a pH of 7.2 to 7.6 in a non-tumor microenvironment of at least about 3:1.
